The versatile role of HuR in Glioblastoma and its potential as a therapeutic target for a multi-pronged attack.
Adv Drug Deliv Rev
; 181: 114082, 2022 02.
Article
em En
| MEDLINE
| ID: mdl-34923029
ABSTRACT
Glioblastoma (GBM) is a malignant and aggressive brain tumor with a median survival of â¼15 months. Resistance to treatment arises from the extensive cellular and molecular heterogeneity in the three major components glioma tumor cells, glioma stem cells, and tumor-associated microglia and macrophages. Within this triad, there is a complex network of intrinsic and secreted factors that promote classic hallmarks of cancer, including angiogenesis, resistance to cell death, proliferation, and immune evasion. A regulatory node connecting these diverse pathways is at the posttranscriptional level as mRNAs encoding many of the key drivers contain adenine- and uridine rich elements (ARE) in the 3' untranslated region. Human antigen R (HuR) binds to ARE-bearing mRNAs and is a major positive regulator at this level. This review focuses on basic concepts of ARE-mediated RNA regulation and how targeting HuR with small molecule inhibitors represents a plausible strategy for a multi-pronged therapeutic attack on GBM.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Uridina
/
Neoplasias Encefálicas
/
Adenina
/
Glioblastoma
/
Proteína Semelhante a ELAV 1
Limite:
Humans
Idioma:
En
Revista:
Adv Drug Deliv Rev
Ano de publicação:
2022
Tipo de documento:
Article